[2] MEIJERS B K， EVENEPOEL P. The gut-kidney axis： indoxyl sulfate， p-cresyl sulfate and CKD progression[J]. Nephrol Dial Transplant，2011，26（3）：759-761.
[3] RITZ E. Intestinal-renal syndrome：mirage or Reality?[J]. Blood Purification， 2011， 31（1-3）： 70-76.
[7] SABATINO A， REGOLISTI G， BRUSASCO I， et al. Alterations of intestinal barrier and microbiota in chronic kidney disease[J]. Nephrol Dial Transplant， 2015， 30（6）： 924-933.
[8] FIACCADORI E， COSOLA C， SABATINO A. Targeting the gut for early diagnosis， prevention， and cure of diabetic kidney disease： is the phenyl sulfate story another step forward?[J]. Am J Kidney Dis， 2020， 75（1）： 144-147.
[9] SUN G， YIN Z， LIU N， et al. Gut microbial metabolite TMAO contributes to renal dysfunction in a mouse model of diet-induced obesity[J]. Biochem Biophys Res Commun，2017，493（2）：964-970.
[12] PIENIAZEK A， GWOZDZINSKI L， HIKISZ P，et al. Indoxyl sulfate generates free radicals， decreases antioxidant defense， and leads to damage to mononuclear blood cells[J]. Chem Res Toxicol，2018，31（9）： 869-875.
[13] LIU W C， TOMINO Y， LU K C. Impacts of indoxyl sulfate and p-cresol sulfate on chronic kidney disease and mitigating effects of AST-120[J]. Toxins， 2018， 10（9）： 367.
[18] CHENG X， ZHOU T， HE Y， et al. The role and mechanism of butyrate in the prevention and treatment of diabetic kidney disease[J]. Front Microbiol，2022，13：961536.
